Combined inhibition of PI3K and PARP is effective in the treatment of ovarian cancer cells with wild-type PIK3CA genes
详细信息 查看全文
- 作者：Dong Wanga ; b ; 1 ; Chengbo Lic ; 1 ; Yuan Zhanga ; Min Wanga ; Nan Jianga ; Lin Xianga ; Ting Lia ; Thomas M. Robertsd ; Jean J. Zhaod ; jean_zhao@dfci.harvard.edu" class="auth_mail" title="E-mail the corresponding author ; Hailing Chenga ; hailingcheng_dmu@163.com" class="auth_mail" title="E-mail the corresponding author ; Pixu Liua ; pixu_liu@dmu.edu.cn" class="auth_mail" title="E-mail the corresponding author
- 关键词：Ovarian cancer ; BKM120 ; Olaparib ; BRCA ; Combination therapy
- 刊名：Gynecologic Oncology
- 出版年：2016
- 出版时间：September 2016
- 年：2016
- 卷：142
- 期：3
- 页码：548-556
- 全文大小：2180 K
文摘
- •
PI3K inhibition induces BRCA downregulation in wild-type PIK3CA ovarian cancer.
- •
PI3K and PARP inhibitors synergistically suppress ovarian cancer cell growth.
- •
BRCA downregulation following PI3K inhibition may predict PARP inhibitor response.